HOUSTON, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today highlighted Nexalin’s rigorous peer-reviewed clinical research validating its proprietary neurostimulation
Cambridge Cognition inks deal with India-based Ivory
Cambridge Cognition announced on Monday that it has entered into a commercialisation agreement with India-based brain health platform Ivory to deploy its ‘CANTAB Pathway’ digital cognitive assessment tool across healthcare and consumer health markets in India.
The AIM-traded neuroscience technology
